“When SG meets “Pembro”

Welcome Scott Tagawa to Dana-Farber Lank Center for Genitourinary Oncology #GU seminars !

Atish Choudhury, MD PhD

Honored to be accepted to the 24th MCCR workshop EORTC AACR ESMO - Eur. Oncology!

Big thanks to Misha Beltran for her continuos support, guidance and sharp thoughts!!

Time to dive into B7-H3 changes in our patients! #MCCRworkshop

Prostate SPORE Retreat 2024 ⁦Felix Feng⁩ ⁦Amina Zoubeidi⁩ ⁦Josh Lang⁩ ⁦PCF Science⁩

The March issue of Cancer Discovery is now online! The cover features work by Gian Marco Franceschini Francesca Demichelis Misha Beltran and colleagues on detection of neuroendocrine prostate cancer through cfDNA methylation - read this and more here: aacrjournals.org/cancerdiscover…

Thrilled to share our years long DOD funded study of circulating biomarkers of anti angiogenic therapy outcomes in mCRPC from CALGB 90401. DCI Center for Prostate & Urologic Cancers w/Susan Halabi and Andy Nixon. trebuchet.public.springernature.app/get_content/d6… Dan George Michael Morris Misha Beltran Prostate Cancer and Prostatic Diseases

Cabo+atezo in CRPC = ⬆️ rPFS (6.3 vs 4.2 mo HR 0.65(0.50-0.84). Immature OS 0.79(0.58-1.07). RR 13 vs 4%.We know Cabo mono has activity, and PD(L)1 has failed in CRPC. Therefore, without a Cabo mono arm it’s hard to know how much atezo is adding. Great job Neeraj Agarwal, MD, FASCO 👌⭐️ #GU24

Our very own, trailblazer Misha Beltran presents promising results in NEPC leveraging DLL3 expression and the immune microenvironment!

ASCO Dana-Farber Lank Center for Genitourinary Oncology OncLive.com OncoAlert #GU24

HPN328 is a tri-specific T cell engager (x CD3+ albumin). X is ⬆️ in neuroendocrine prostate cancer. HPN328 is well tolerated (Cytokine release syndrome, SOB,fatigue) and active (SD in almost all NE CRPC ). Along with STEAP1 this is opening a new chapter of IO in CRPC #GU24

Excited to share our newly published manuscript which provides treatment recommendations for large cell neuroendocrine prostate cancer The Oncologist Lurie Cancer Center Misha Beltran Tamara Lotan, MD David VanderWeele MD PhD Fatima Yaftali Karzai, M.D. Ravi A Madan M.D. & Maha Hussain

academic.oup.com/oncolo/advance…

Now online in Cancer Discovery - Non-invasive Detection of Neuroendocrine #ProstateCancer through Targeted Cell-Free DNA Methylation by Gian Marco Franceschini Francesca Demichelis Misha Beltran and colleagues doi.org/10.1158/2159-8… Università di Trento Dana-Farber #LiquidBiopsy #cfDNA

Prostate cancer research: Dana-Farber team led by Himisha Beltran, MD, (@mishabeltran) develops blood test that distinguishes neuroendocrine #ProstateCancer subtype. Collaborated with Università di Trento and findings published in Cancer Discovery.

Read more here: ms.spr.ly/6016imMxO

Noninvasive detection of NEPC by targeted cfDNA methylation Cancer Discovery co-led by Francesca Demichelis and her lab Università di Trento. Congrats to first author Gian Marco Franceschini and thank you to many amazing collaborators PCF Science Dana-Farber Lank Center for Genitourinary Oncology #NEMO

aacrjournals.org/cancerdiscover…

#APCCC24 Lugano 2024 👏- Unique way to learn and chat with the world experts on #ProstateCancer
Registration on apccc.org
European Association of Urology (EAU) UroUpdate GeSRU Advanced Prostate Cancer Consensus Conference Misha Beltran Elena Castro Yüksel Ürün Anders Bjartell

Honored to receive the CURE Mentor Appreciation Award.

Thanks to Misha Beltran for being extremely supportive in co-mentoring students with me.

Fortunate to mentor outstanding students, Osasenaga Idahor and Kenny Weng, in the DF/HCC CURE program.
dfhcc.social-previews.top/cvguwtu6

Congratulations Andrew Goldstein and team! Honored to discuss your work in this News & views Nature Cell Biology with Martin Bakht Dana-Farber rdcu.be/dsJN3

This means so much to me. The first truly new direction I took as a professor. It began in 2017 when my first student Preston Crowell figured out how to metabolically profile basal and luminal cells. It's grown into the paper I'm most proud of in my career
nature.com/articles/s4155…

5 years from pitching trial Regeneron to publication Cancer Cell. Science is hard, but living with cancer is so much harder!

Thank you to patients and families 🫶🏼 for participating in and contributing to science. We hope it has tsunami 🌊 (not ripples) of impact. /11